References
- Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol 2007;3:137-158
- Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64:543-552
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV, 4th edn. American Psychiatric Association, 1994
- National Institute of Mental Health. Bipolar disorder. National Institutes of Health 2009; Available at: URL: http://www.nimh.nih.gov/health/publications/bipolar-disorder/index.shtml. Accessed March 16, 2010
- Buckley PF. Update on the treatment and management of schizophrenia and bipolar disorder. CNS Spectr 2008;13(Suppl 1):1-10
- Hassan M, Madhavan SS, Kalsekar ID, et al. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder. Ann Pharmacother 2007;41:1812-1818
- Moller HJ, Nasrallah HA. Treatment of bipolar disorder. J Clin Psychiatry 2003;64(Suppl 6):9-17
- Berk L, Hallam KT, Colom F, et al. Enhancing medication adherence in patients with bipolar disorder. Hum Psychopharmacol 2010;25:1-16
- Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002;63:384-390
- Hassan M, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health Syst Pharm 2009;66:358-365
- Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry 2002;159:1927-1929
- Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-811
- Depp CA, Moore DJ, Patterson TL, et al. Psychosocial interventions and medication adherence in bipolar disorder. Dialogues Clin Neurosci 2008;10:239-250
- Love RC. Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm 2002;59(Suppl 8):S10-S15
- McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006;67:15-18
- Keks NA, Ingham M, Khan A, et al. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry 2007;191:131-139
- Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull 2007;33:1379-1387
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619
- Sajatovic M, Bauer MS, Kilbourne AM, et al. Self-reported medication treatment adherence among veterans with bipolar disorder. Psychiatr Serv 2006;57:56-62
- Lage MJ, Hassan MK. The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. Ann Gen Psychiatry 2009;8:7
- Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006;8:232-241
- Gianfrancesco FD, Sajatovic M, Rajagopalan K, et al. Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder. Clin Ther 2008;30:1358-1374